Lupin shares to be in focus on Thursday as USFDA approves Dapagliflozin and Metformin tablets

USFDA approvals are crucial catalysts for Indian pharma companies, signaling market access and revenue potential. The diabetes segment is a high-growth area globally.

Focus on pharma stocks with recent USFDA approvals; look for sustained upward momentum post-announcement with strict stop-losses.

For Indian markets, this story mainly matters for LUPIN and the Pharmaceuticals pocket. The current signal is bullish, so traders should look for follow-through in price, volume, and sector breadth instead of reacting to the headline alone.

Watch whether the next market session confirms the setup described here: Received US FDA approval for a key diabetes medication, opening up a new revenue stream in the US market. Also track volume confirmation, sector participation, and whether the move holds beyond the first reaction.

• •Lupin received U.S. FDA approval for Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets.
• •The approval is expected to attract investor attention to Lupin's shares.
• •Risk flag: Pricing pressure in the generic market
• •Risk flag: Competition from other generic manufacturers
• •Risk flag: Regulatory changes in the US